Nature Medicine, Published online: 14 April 2026; doi:10.1038/d41591-026-00020-8 A phase 1 study evaluating setidegrasib shows promising safety and clinical activity, establishing targeted protein degradation as a viable new approach for treating KRAS G12D-driven solid tumors.
Nature Medicine published a clinical update in Research Highlights on 14 Apr 2026. The item focuses on KRAS-targeting PROTAC drug passes first clinical test. Open the detail page to review the full original feed content.